StockNow
Log in
Global MarketsIMPORTANT

AstraZeneca (AZN LN) Q2 2026 (USD): Revenue 15.4bln (exp. 15.3bln), adj. EPS 2.63 (exp. 2.50)

StockNow breaking-news AI analysis

AstraZeneca beat Q2 2026 expectations, raised dividends, and reaffirmed its USD 80bn revenue goal, supported by over 20 high-value pipeline readouts expected over the next 18 months.

News detail

Interim dividend of USD 1.06/shr (prev. 1.03/shr)Sales Breakdown Product: 14.51bln, +5% Alliance: 874mln, +34% CEO "We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months" "...on track to deliver our USD 80bn Total Revenue ambition, which assumes successes and setbacks"

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)